Understanding mechanisms by which microbially derived metabolites regulate host GUT inflammation

Active Project Grant Awarded Last action

Award ID
F32DK138598
Recipient
Awarding agency
Obligated
$679,736

Award facts

Completion date 86% complete
Place of performance
California, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Chronic inflammation is a rising health issue that affects millions of people worldwide. Emerging evidence shows that dysbiosis of the GUT microbiota can lead to changes in the production of microbial-derived metabolites (mdms), which contribute to inflammation and the onset of inflammatory diseases, such as cancer, non-alcoholic fatty liver disease, and inflammatory bowel syndrome. Mdms are absorbed into host circulation through the GUT and regulate immune responses. A key immune cell type at the interface of host-microbe interactions is macrophages, which maintain tissue homeostasis, and are key contributors to chronic inflammation. To date, few mdms with well-studied cellular and molecular mechanisms describing the interplay between microbes and our immune system are known. Using metabolomics data from a dietary intervention study that found distinct immunological trajectories based on microbiota diversity, as well as data from a 176 GUT microbiota strain library we identified 18 human-immune associated mdms. Here we aim to determine the regulatory role of mdms on the host immune system through a direct effect on macrophages. The impact of these mdms on host molecular pathways will be characterized using murine and human macrophage cells, NFB reporter lines, crispr/CAS9 systems, gpcr reporter lines and in vivo using IBD murine models (AIM1). On the microbe end, i will determine the metabolic pathways responsible to produce these immune-associated mdms and generate knock-out or knock-in bacterial strains. I will perform a series of highly-controlled mouse experiments to determine the specific microbial components responsible for mdms immune modulating effects (AIM2). My previous experience in immune regulation and animal models make me well-equipped to analyze and perform these technical experiments, and the expertise in microbial genetics and metabolomics facilities honed by my mentoring team make stanford university an ideal location to learn the skills i will need to perform these experiments. Completion of these aims will increase the understanding of the microbiota-host interaction during times of homeostasis and acute or chronic inflammation, which will pave the way for the development of precision therapeutic strategies to reduce chronic inflammation and prevent acute disease.

Transactions

Action Obligated Date
Amendment $1,356
Amendment $80,224
Amendment $80,224
Amendment $1,284
Amendment $1,284
Amendment $76,756
Amendment $76,756
Amendment $4,784
Amendment $4,784
Amendment $4,784
Amendment $69,500
Amendment $69,500
Amendment $0
Amendment $0
Amendment $69,500
Amendment $0
Amendment $69,500
Amendment $0
Original award $69,500
Show all 19

Quick answers

Who received award F32DK138598?

F32DK138598 was awarded to The Leland Stanford Junior University by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on August 28, 2024.

How much is award F32DK138598 worth?

$679,736 has been obligated on F32DK138598.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login